Susan Low is the VP of Preclinical Development at eGenesis.
She has 20 years of experience in scientific research, including in vitro and in vivo pharmacology, DMPK and toxicology across multiple therapeutic areas including hemophilia, oncology and neurological disorders, spanning antibody, Fc-fusion protein, polymeric nanoparticles and extended-release solid oral dosage form drug products. Prior to eGenesis, Susan served as VP of Preclinical Development at Verseau Therapeutics, where she played a key role in advancing the company’s first macrophage repolarizer into the clinic.
Susan holds a B.S. in Pharmacology and a Ph.D. in Molecular Endocrinology both from the University of Edinburgh, Scotland.